- Home
- SST vs ANL Comparison
SST vs ANL Comparison
Compare SST & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SST | ANL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SST | ANL |
|---|---|---|
| Price | $4.36 | $0.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 27.5K | 13.2K |
| Earning Date | 11-05-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.88 |
| 52 Week High | $15.00 | $2.99 |
Technical Indicators
Market Signals| Indicator | SST | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 22.30 |
| Support Level | $3.54 | $1.32 |
| Resistance Level | $4.01 | $1.59 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 60.82 | 5.70 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.